选择性联合用药介入治疗少血供肝脏转移瘤的研究

Clinical study on hypovascular liver metastatic tumor treated by selectivity drug combination with interventional chemotherapy

目的:探讨选择性联合用药肝动脉灌注(hepatic-arterial infusion,HAI)化疗少血供肝脏转移瘤的疗效。方法:随访观察2004年1月-2007年1月间采用肝动脉灌注化疗少血供肝脏转移瘤68例。以是否针对原发肿瘤选择性联合用药分为两组。结果:常规联合用药组40例,近期客观有效9例(22.5%),中位生存期8个月,存活半年22例(55.0%),存活1年11例(27.5%),最长存活16个月。选择性联合用药组28例,近期客观有效13例(46.6%),中位生存期13个月,存活半年21例(75.0%),存活1年18例(64.3%),最长存活43个月。2组间近期客观有效率有差异(P<0.05);半年存活率无差异(P>0.05);1年存活率有明显差异(P<0.01)。结论:选择性联合用药肝动脉灌注治疗少血供肝脏转移瘤可提高治疗效果延长生存期。

Objective：To investigate the effect of selectivity drug combination on hypovascular liver metastatic tumor by hepatic - arterial infusion with interventional chemotherapy. Methods： Sixty - eight patients with hypovascular liver metastatic tumor were followed up which were treated by hepatic - arterial infusion chemotherapy from 2004 January to 2007 January. Wether they aimed directly at primartumor by selectivity drug combination,we divided them into two groups. Results： Early complete response （CR） was observed in 13 cases（46. 6% ） in selectivity drug combination group（ 28 patients） ,9 cases（22.5% ）in convention drug combination group （40 patients） ,there was significant difference of CR between two groups（ P 〈 0.05 ）. The 6,12 - month survival rates for the 28 patients were 75. 0% （21 patients） ,64.3% （ 18 patients） ,the median survival time and the longest survival time was 13 month and 43 month respectively, for the 40 patients were 55.0% （22 patients）, 27.5 % （ 11 patients）, the median survival time and the longest survival time was 8 month and 16 month respectively. There was no significant difference of 6 -month survival rates between two groups （P 〉 0.05 ）. There was significant difference of 12 -month survival rates between two groups （P 〈 0.05 ）. Conclusion： Selectivity drug combination on hypovascular liver metastatic tumor by hepatic - arterial infusion with interventional chemotherapy may improve the therapeutic efficacy and prolong life span.